All In Biotech

Drug Trial Radar · NCT07759869

A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety of HS-10380 in Chinese Adult Patients With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Jul 31, 2028

Study completion Aug 31, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse events leading to study drug discontinuationin Chinese adult participants with schizophrenia.

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Interventions

  • HS-10380Drug

    Oral;QD;W1:dose titration; W1-2:dose adjust to optimal level;Week 3-52:stable dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AE)Time frame: From first dose to end of study (Up to approximately 54 weeks )
  2. Incidence and severity of serious adverse events (SAE)Time frame: From first dose to end of study (Up to approximately 52 weeks)
  3. Incidence of Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug DiscontinuationTime frame: From first dose to end of study (Up to approximately 54 weeks )

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Sixth Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.